Myeloid malignancies should be ruled out in any patient with abnormal blood count if no other obvious cause is established. Test is for patients with:
Abnormal blood count
-Low or high hemoglobin
-Low or high white cells count
-Low or high platelets count
Past or present cancer
When caught early, hematologic malignancies can be managed easily with significant improvement in quality of life. The GTC-Hematology Profile is a test specifically designed to help in the diagnosis and monitoring of hematologic neoplasms without the need for bone marrow biopsy. The GTC- Hematology Profile uses state- of the art Next Generation Sequencing (NGS) to confirm or rule out
-Myelodysplastic syndrome (MDS)
-Chronic myelomonocytic leukemia (CMML)
-Myeloproliferative neoplasm other than CML (MPN)
-Possible other malignancies (Mastocytosis, Lymphom, Multiple Myeloma,..)
-Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS)
The Test can detect any of the above disease at a very early stage before it can be confirmed by microscopic evaluation and bone marrow. Because the test can detect low level mutations, this has been reported to be an independent predictor for cardiovascular disease. Patients with low level mutations are at a 4-time greater risk of developing myocardial infarction.
5-10 mL Blood (EDTA tube)
Ship using cold pack. The cold pack should not directly contact blood. Ship as soon as sample is collected with overnight delivery.
Turn Around Time:
Hematopoiesis – the formation of blood cellular components – occurs during embryonic development and throughout adulthood to produce and replenish the blood system. Studying hematopoiesis can help scientists and clinicians to better understand the processes behind blood disorders and cancers.